
1146629-84-6 Ruxolitinib
CAS:1146629-84-6. MF:C17H26BN3O2. MW:315.22. EINECS:. MDL No.:MFCD16038968
Add to Inquiry![CAS 643068-20-6 | 6-Oxabicyclo[3.2.1]octan-7-one, 4-bromo-, (1R,4S,5R)-](/uploads/41320/small/cas-643068-20-6-d8ec5.jpg)
CAS 643068-20-6 | 6-Oxabicyclo[3.2.1]octan-7-one, 4-bromo-, (1R,4S,5R)-
Name: 6-Oxabicyclo[3.2.1]octan-7-one,4-bromo-,(1R,4S,5R)-MF: C7H9BrO2MW: 205.05CAS: 643068-20-6
Add to Inquiry![CAS 632322-61-3 | 1-((2'-Cyano-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1h-benzo[d]imidazole-7-carboxylic Acid](/uploads/41320/small/cas-632322-61-3-19f80.jpg)
CAS 632322-61-3 | 1-((2'-Cyano-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1h-benzo[d]imidazole-7-carboxylic Acid
Name: 1-(2'-cyanobiphenyl-4-yl)Methyl-2-ethoxy-1H-benziMediazole-7-carboxylic acidCAS number: 632322-61-3Molecular formula: C24H19N3O3Molecular weight: 397.43EINECS number:MDL No.:MFCD27996073
Add to Inquiry
CAS 40337-66-4 | 4-(3-Bromopropyl)pyridine
Name: 4-(3-BROMO-POPYL)-PAYRIDINECAS number: 40337-66-4Molecular formula: C8H10BrNMolecular weight: 200.08EINECS number:MDL No.:MFCD07785861
Add to Inquiry
CAS 102-97-6 | N-Isopropylbenzylamine
Name: N-IsopropylbenzylamineCAS number: 102-97-6Molecular formula: C10H15NMolecular weight: 149.23EINECS number: 203-067-6MDL No.:MFCD00008863
Add to Inquiry
68077-26-9 NORFLOXACIN Q-ACID
CAS:68077-26-9MF:C12H9ClFNO3MW:269.66EINECS:614-262-4MDL No.:MFCD00792459
Add to Inquiry
CAS 1428243-26-8 | (3R,4S)-3-(2-Bromoacetyl)-4-ethyl-1-pyrrolidinecarboxylic acid phenylmethyl ester
Product name: (3R, 4S) -3- (2-Bromoacetyl) -4-ethyl-1-pyrolidinecarboxylic acid phenylmethyl esterCAS number: 1428243-26-8Molecular formula: C16H20BrNO3Molecular weight: 354.24EINECS number:MDL
Add to Inquiry
143900-44-1 Ibrutinib Intermediate
CAS:143900-44-1. MF:C10H19NO3. MW:201.26. EINECS:1308068-626-2. MDL No.:MFCD06659041
Add to Inquiry
571188-59-5 Tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate
CAS:571188-59-5. MF:C14H22N4O2. MW:278.35. EINECS:695-268-4. MDL No.:MFCD11594962
Add to Inquiry
134790-39-9
CAS:134790-39-9. MF:C23H19F2N3O6. MW:471.41. EINECS:603-873-1. MDL No.:MFCD09837611
Add to Inquiry
79832-89-6
CAS:79832-89-6. MF:C17H25Br. MW:309.28. EINECS:616-745-5. MDL No.:MFCD00577359
Add to Inquiry
3-quinuclidinone Hydrochloride 1193-65-3
CAS:1193-65-3. MF:C7H12ClNO. MW:161.63. EINECS:214-776-5. MDL No.:MFCD00137391
Add to Inquiry
China Ruxolitinib intermediate Manufacturers Factory Suppliers
Our company has introduced many sets of advanced processing equipment and technology to expand the processing capacity of our Selexipag intermediate, distribution intermediate, assembled unit intermediate .Dedicated to strict quality management and thoughtful client services, our experienced staff customers are generally available to discuss your demands and guarantee full client pleasure for Ruxolitinib intermediate. All our ideas are based on the experience of customers and users! We offer customization services to meet your unique needs. We offer comprehensive customer support services to ensure the success of our customers. We would make friends with businessmen from at home and abroad, following the purpose of 'Quality First, Reputation First, the Best Services'. We are always ready to provide technical consulting services for various products.WEBAbstract Patients with myelofibrosis at intermediate-1 risk according to the International Prognostic Score System are projected to a relatively ... At 3 months, ruxolitinib-induced grade 3 anemia...
WEBJul 5, 2021 · 1. INTRODUCTION. Ruxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor that has demonstrated durable improvements in splenomegaly, myelofibrosis (MF)‐related symptoms, and...
WEBOct 27, 2023 · 25,000 to <35,000/mm 3 AND decline in platelet count is <20% during the prior 4 weeks. Reduce ruxolitinib dosage by 5 mg once daily. For patients currently receiving 5 mg once...
WEBIntermediates of Ruxolitinib, offered by us can be seen from the list shown below. Please click on the intermediate name to browse through more details of the intermediate required by you. Suppose...
WEBMay 20, 2021 · Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M, et al. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis:...
WEBThe most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and...
